Collaborations

The company has collaboration agreements with the Foundation for Biomedical Research at the Puerta de Hierro University Hospital (Madrid, Spain) focused on conducting immunogenicity, pharmacokinetics and biodistribution studies in mice; the Centre for Applied Medical Research (CIMA, Pamplona, Spain) to address the in vivo efficacy of Trimerbody-based molecules in experimental models of cancer; and the Research Biomedicine Institute Alberto Sols (IIBm, Madrid, Spain) to assess the intracellular signaling events induced by specific candidate molecules. In addition, the company is collaborating with the Spanish National Cancer Research Center (CNIO, Madrid, Spain) to address the structures of the Trimerbody-based molecules.

Latest News

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models
13-01-2021

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer
10-11-2020

...